Zoleikha Golipoor
Overview
Explore the profile of Zoleikha Golipoor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
118
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramezani M, Komaki A, Hashemi-Firouzi N, Mortezaee K, Faraji N, Golipoor Z
J Chem Neuroanat
. 2024 Apr;
138:102425.
PMID: 38663119
No abstract available.
2.
Ale Mahmoud Mehraban R, Babaei P, Rohampour K, Jafari A, Golipoor Z
Iran J Basic Med Sci
. 2024 Feb;
27(3):360-365.
PMID: 38333746
Objectives: Metformin, as an insulin sensitizer, is a familiar antidiabetic drug. Increasing evidence points to metformin's protective effects against Alzheimer's disease (AD). However, the mechanism is not well understood. The...
3.
Kazemi S, Safari S, Komaki S, Karimi S, Golipoor Z, Komaki A
CNS Neurosci Ther
. 2023 Sep;
30(3):e14459.
PMID: 37727020
Aims: Alzheimer's disease (AD) is the most common type of dementia in which oxidative stress plays an important role. In this disease, learning and memory and the cellular mechanism associated...
4.
Asadbegi M, Komaki H, Faraji N, Taheri M, Safari S, Raoufi S, et al.
Psychopharmacology (Berl)
. 2023 Feb;
240(4):951-967.
PMID: 36811650
Rationale: Aging is the major risk factor for Alzheimer's disease (AD), and cognitive and memory impairments are common among the elderly. Interestingly, coenzyme Q10 (Q10) levels decline in the brain...
5.
Naeimi A, Zaminy A, Amini N, Balabandi R, Golipoor Z
BMC Neurosci
. 2022 Nov;
23(1):65.
PMID: 36384473
Background: One of the most serious nervous system diseases is spinal cord injury(SCI), which is increasing for various reasons. Although no definitive treatment has yet been identified for SCI, one...
6.
Faraji N, Salehi I, Alizadeh A, Pourgholaminejad A, Komaki A, Azandaryani M, et al.
Basic Clin Neurosci
. 2022 Jun;
12(6):849-860.
PMID: 35693151
Introduction: Extremely Low-Frequency Electromagnetic Fields (ELF-EMFs) have gathered significant consideration for their possible pathogenicity. However, their effects on the nervous system's functions were not fully clarified. This study aimed to...
7.
Komaki A, Shahidi S, Hashemi-Firouzi N, Rafat Z, Keymoradzadeh A, Golipoor Z
Front Behav Neurosci
. 2022 Mar;
16:796230.
PMID: 35309680
Introduction: Alzheimer's disease (AD) is a neurodegenerative disease that is characterized by amyloid plaque deposits, neuronal cell loss, and memory impairment. Granulocyte-colony stimulating factor (G-CSF) is a growth factor associated...
8.
Ramezani M, Komaki A, Hashemi-Firouzi N, Mortezaee K, Faraji N, Golipoor Z
J Chem Neuroanat
. 2020 May;
108:101804.
PMID: 32470495
The therapy based on mesenchymal stem cells(MSCs) has received growing attraction for Alzheimer's disease(AD). However, a great challenge in this regard is the low survival rate of MSCs following transplantation....
9.
Nasiri E, Alizadeh A, Roushandeh A, Gazor R, Hashemi-Firouzi N, Golipoor Z
Metab Brain Dis
. 2019 May;
34(4):1131-1143.
PMID: 31129766
Currently, mesenchymal stem cells (MSCs) based therapy has extensive attraction for Alzheimer's disease (AD). However, low survival rate of MSCs after transplantation is a huge challenging. The current study aimed...
10.
Rafat A, Roushandeh A, Alizadeh A, Hashemi-Firouzi N, Golipoor Z
Cell J
. 2018 Aug;
20(4):450-458.
PMID: 30123990
Objective: Mesenchymal stem cells (MSC) from various sources have the potentials to positively affect regenerative medicine. Furthermore, pre-conditioning strategies with different agents could improve the efficacy of cell therapy. This...